The Top 2021 Abstracts in Breast Cancer publication provides expert insights on groundbreaking abstracts in breast cancer, with a focus on HER2-positive breast cancer treatment that were presented at medical meetings throughout 2021.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®
March 24, 2022
Video
Debu Tripathy, MD, discusses the implications of results from the phase 3 NALA trial in patients with HER2-positive metastatic breast cancer with brain metastases.
March 23, 2022
Video
Komal Jhaveri, MD, FACP, discusses the implications of the phase 2 TUXEDO-1 trial in patients with HER2-positive metastatic breast cancer with brain metastases.
March 21, 2022
Video
Tiffany A. Traina, MD, discusses the implications of the phase 3 EMERALD trial in advanced estrogen receptor–positive, HER2-negative breast cancer.
March 21, 2022
Video
Komal Jhaveri, MD, FACP, discusses the implications of data from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.
March 16, 2022
Article
Leading oncologists in breast cancer share their perspectives on the biggest abstracts that were presented throughout 2021 .
February 17, 2022
Article
Debasish Tripathy, MD, provides perspective on some of the key data sets that were presented and published in 2021 in HER2-positive breast cancer.